Welcome to our dedicated page for ZimVie news (Ticker: $ZIMV), a resource for investors and traders seeking the latest updates and insights on ZimVie stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZimVie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZimVie's position in the market.
Rhea-AI Summary
ZimVie Inc. (ZIMV) will report its first-quarter financial results on May 8, 2024, after the market closes. The company, a global leader in the dental market, will host a conference call at 4:30 p.m. Eastern Time on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
-
Rhea-AI Summary
ZimVie Inc. completes the sale of its Spine business to H.I.G. Capital for $375 million, establishing a pure-play dental business. The deal includes $315 million in cash and a $60 million promissory note. The company aims for a $455+ million Net Sales and a 15%+ adjusted EBITDA margin one year post-deal closure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.01%
Tags
-
Rhea-AI Summary
H.I.G. Capital announces the acquisition of ZimVie Inc.'s Spine division, now operating as Highridge Medical. Highridge is a leader in the global spinal device market, with a strong bone healing therapies portfolio. The Company will be led by experienced industry executives and aims to enhance spine care through R&D and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.01%
Tags
Rhea-AI Summary
ZimVie Inc. will participate in the 23rd Annual Needham Virtual Healthcare Conference on April 10th, 2024. The company is a global leader in dental and spine markets, offering a live webcast of the event on their website for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
-
Rhea-AI Summary
ZimVie Inc. reports FY 2023 Third Party Net Sales of $457.2 million from Continuing Operations and $409.2 million from Discontinued Operations. The company plans to complete the sale of its Spine Business for $375M in 1H 2024, focusing on becoming a pure play dental company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.52%
Tags
-
Rhea-AI Summary
ZimVie Inc. (Nasdaq: ZIMV) will release financial results for Q4 and full-year 2023 on February 28, 2024. A conference call will follow at 4:30 p.m. Eastern Time. Interested parties can register online. Webcast replay available at investor.zimvie.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
Rhea-AI Summary
ZimVie Inc. (Nasdaq: ZIMV) announces the launch of the TSX Implant in Japan, designed for immediate extraction and standard loading protocols. The implant aims to deliver peri-implant health, crestal bone maintenance, long-term osseointegration, and prosthetic stability. Integrated with ZimVie’s end-to-end digital workflows, the TSX Implant furthers ZimVie’s commitment to simplify procedures and optimize practice protocols. The company aims to solidify its position as the market leader in Japan with this launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
-
News
Rhea-AI Summary
ZimVie Inc. (Nasdaq: ZIMV) has entered into a definitive agreement to sell its spine business to H.I.G. Capital for $375 million, with $315 million in cash and $60 million in the form of a promissory note. The net proceeds will be used to pay down debt and support dental growth initiatives, allowing the company to streamline operations and focus as a pure-play dental company. The deal is expected to be accretive to ZimVie’s revenue growth rate, EBITDA margin, and cash flow conversion rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.41%
Tags
-
Rhea-AI Summary
ZimVie Inc. (Nasdaq: ZIMV) has received FDA clearance for its Vital™ Spinal Fixation System, a result of the Development Cooperation Agreement with Brainlab Spine & Trauma Navigation. The company plans to co-market Brainlab Spine & Trauma Navigation alongside its Vital and Virage lines, with first Vital sets expected to be launched in the United States in early 2024. ZimVie also plans to submit a 510(k) application to the FDA for Virage next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
Rhea-AI Summary
ZimVie Inc. reported financial results for Q3 2023, with third party net sales of $202.9 million, a net loss of ($5.1) million, and adjusted net income of $2.2 million. Diluted EPS was ($0.19), while adjusted diluted EPS was $0.08. The company's adjusted EBITDA was $25.8 million, with an adjusted EBITDA margin of 12.7%. ZimVie ended the quarter with a cash balance of $75.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.55%
Tags
ZimVie Inc.
Nasdaq:ZIMV
ZIMV Rankings
ZIMV Stock Data
430.91M
21.40M
1.76%
98.59%
2.9%
Dental Equipment and Supplies Manufacturing
Manufacturing
United States of America
WESTMINSTER